# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price tar...
HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May ...
- SEC Filing
HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.